
Akums Drugs & Pharmaceuticals Ltd is Rated Buy
2026-11-15 10:10:29Akums Drugs & Pharmaceuticals Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 3 November 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 November 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.
Read MoreAkums Drugs & Pharmaceuticals Gains 0.17%: 5 Key Factors Driving the Week
2026-11-07 10:03:40Key Events This Week 2 Nov: Stock opens at Rs.731.50, marginally down -0.05% 3 Nov: Strong gap up and upper circuit hit at Rs.806.45 4 Nov: Quality grade upgraded to good; Mojo Grade upgraded to Buy 5 Nov: Price consolidates amid mixed volume 6 Nov: Week closes at Rs.733.15, +0.17% for the week Week OpenRs.731.50 <div class="s...
Read More
Akums Drugs & Pharmaceuticals Ltd Upgraded to Buy on Strong Financial and Quality Metrics
2026-11-04 08:42:55Akums Drugs & Pharmaceuticals Ltd has seen its investment rating upgraded from Hold to Buy following a comprehensive reassessment of its financial performance, valuation metrics, quality indicators, and technical outlook. The upgrade reflects the company’s robust quarterly results, improved profitability ratios, fair valuation compared to peers, and positive market momentum, signalling renewed investor confidence in this small-cap pharmaceutical player.
Read More
Akums Drugs & Pharmaceuticals Ltd: Valuation Shift Enhances Price Attractiveness Amid Strong Returns
2026-11-04 08:01:53Akums Drugs & Pharmaceuticals Ltd has recently undergone a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change, coupled with strong operational metrics and a robust share price performance, has enhanced the stock’s price attractiveness for investors within the Pharmaceuticals & Biotechnology sector.
Read More
Akums Drugs & Pharmaceuticals Ltd Upgrades Quality Grade Amid Strong Financial Metrics
2026-11-04 08:00:13Akums Drugs & Pharmaceuticals Ltd has seen a notable upgrade in its quality grade from average to good, reflecting significant improvements in its business fundamentals. With a current Mojo Score of 74.0 and an upgraded Mojo Grade to Buy from Hold as of 3 Nov 2026, the company’s financial health and operational efficiency have strengthened, positioning it favourably within the Pharmaceuticals & Biotechnology sector.
Read More
Akums Drugs & Pharmaceuticals Ltd is Rated Hold
2026-10-30 10:10:24Akums Drugs & Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 October 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.
Read More
Akums Drugs & Pharmaceuticals Ltd is Rated Hold
2026-10-19 10:10:22Akums Drugs & Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO. This rating was last updated on 13 August 2026, reflecting a reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 19 October 2026, providing investors with the most recent data to inform their decisions.
Read More
Akums Drugs & Pharmaceuticals Ltd Sees Technical Momentum Shift Amid Mixed Market Signals
2026-10-12 08:03:55Akums Drugs & Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a bullish to a mildly bullish stance as of October 2026. Despite a recent 4.44% decline in its share price, the stock continues to demonstrate resilience with mixed signals from key technical indicators such as MACD, RSI, and moving averages, reflecting a nuanced outlook for investors in the pharmaceuticals and biotechnology sector.
Read More
Akums Drugs & Pharmaceuticals Ltd is Rated Hold
2026-10-08 10:11:08Akums Drugs & Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 October 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Read MoreAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
10-Nov-2026 | Source : BSEIntimation of Schedule of the Investors/Analysts Meet
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
05-Nov-2026 | Source : BSETranscript of the Earning/Quarterly Conference Call on the unaudited financial results for the quarter and half year ended on September 30 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
03-Nov-2026 | Source : BSEAudio recording of Earning/ Quarterly Conference Call
Corporate Actions
No Upcoming Board Meetings
Akums Drugs & Pharmaceuticals Ltd has declared 50% dividend, ex-date: 03 Jul 26
No Splits history available
No Bonus history available
No Rights history available